Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell 6Leukemia, Lymphocytic, Chronic, B-Cell 6Lymphoma, Non-Hodgkin 4Recurrence 3Lymphoma, Large B-Cell, Diffuse 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Prolymphocytic, T-Cell 2Leukemia 2Squamous Cell Carcinoma of Head and Neck 1Neoplasms, Plasma Cell 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Lymphoid 1Leukemia, Large Granular Lymphocytic 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Enteropathy-Associated T-Cell Lymphoma 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 28fludarabine phosphate 22Peripheral Blood Stem Cell Transplantation 22Whole-Body Irradiation 18Etoposide 17Mycophenolic Acid 14Doxorubicin 13Tacrolimus 12Vincristine 11Prednisone 11Cyclosporine 11Methotrexate 10Busulfan 10Melphalan 9Bortezomib 9Rituximab 8Antilymphocyte Serum 8Filgrastim 7Carboplatin 7Radiotherapy 6Lenalidomide 6Everolimus 6romidepsin 5Vorinostat 5Therapeutics 5etoposide phosphate 4Sirolimus 4Panobinostat 4Immunohistochemistry 4Ifosfamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Immunoblastic Lymphadenopathy × duvelisib × Clear all
NCT04803201 2026-06-02

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Alliance for Clinical Trials in Oncology

Phase 2 Suspended
170 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡